Articles by Liquidity Services

Problem: A variety of factors can result in obsolete laboratory equipment and R&D devices. Project
completion, equipment upgrade, lab closure, and downsizing all create surplus pharmaceutical assets
no longer required in the same capacity—or at all. Given budget restrictions and the importance placed
on environmentally-sound business practices, organizations can’t afford to allow surplus assets to lie
idle or dispose of them without thought to the process. Surplus requires an innovative and sustainable
process that supports strategic business goals.

Problem: Whether due to mergers and acquisitions, lab downsizing, upgrading or outsourcing, many pharmaceutical and biotech companies—large and small—are opting to sell R&D or manufacturing equipment no longer needed in their own labs. This presents a great opportunity for other institutions to obtain late-model, quality equipment at a reduced cost, direct from the working lab. While purchasing second-hand equipment can be a cost effective and socially acceptable way to go, there are potential pitfalls buyers should look out for including: unreliable sellers, equipment contamination, hidden fees, and unverified purchasing channels.